Active, not recruitingPhase 3NCT01906814

Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation

Studying Hereditary retinoblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sun Yat-sen University
Principal Investigator
Huasheng Yang, Doctor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Intervention
3 cycles chemotherapy(drug)
Enrollment
179 enrolled
Eligibility
All sexes
Timeline
20132024

Study locations (1)

Collaborators

Fudan University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01906814 on ClinicalTrials.gov

Other trials for Hereditary retinoblastoma

Additional recruiting or active studies for the same condition.

See all trials for Hereditary retinoblastoma

← Back to all trials